Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents (Q22241419)

Dimensions Publication ID

Dimensions

6 February 2023

Sally A. Berry

2

Sally A.

Berry

1 reference

Dimensions Publication ID

Dimensions

1050616713

The MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-Type ADHD in a Multisite Study

6 February 2023

language of work or name

English

0 references

publication date

February 2012

0 references

published in

Drugs

0 references

volume

72

0 references

issue

3

0 references

page(s)

309-325

0 references

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication--Adolescent Supplement (NCS-A)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Psychiatric disorders and sexual risk among adolescents in mental health treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Road trauma in teenage male youth with childhood disruptive behavior disorders: a population based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

The longitudinal course of comorbid oppositional defiant disorder in girls with attention-deficit/hyperactivity disorder: findings from a controlled 5-year prospective longitudinal follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Adolescent clinical outcomes for young people with attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, mul

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

A clinical review of outcomes of the multimodal treatment study of children with attention-deficit/hyperactivity disorder (MTA).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Stimulant treatment in children with attention-deficit/hyperactivity disorder moderates adolescent academic outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Stimulant treatment over five years: adherence, effectiveness, and adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Psychiatric and psychosocial predictors of substance use disorders among adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599580-000000000-00000

Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

12 December 2020

Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder.

1 reference

12 December 2020

Teacher reports of DSM-IV ADHD, ODD, and CD symptoms in schoolchildren

1 reference

12 December 2020

A randomized, double-blind, multicenter, parallel-group, placebo-controlled, dose-optimization study of the methylphenidate transdermal system for the treatment of ADHD in adolescents

1 reference

12 December 2020

Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder

1 reference

12 December 2020

Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and D,L-methylphenidate and placebo in a laboratory classroom setting.

1 reference

12 December 2020

Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders

1 reference

12 December 2020

The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study

1 reference

12 December 2020

Treatment of ADHD in children with tics: a randomized controlled trial

1 reference

12 December 2020

When two isn't better than one: predictors of early sexual activity in adolescence using a cumulative risk model

1 reference

12 December 2020

Mechanism of action of methylphenidate: insights from PET imaging studies

1 reference

12 December 2020

A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis

1 reference

12 December 2020

Time course of treatment effect of OROS® methylphenidate in children with ADHD.

1 reference

12 December 2020

Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study

1 reference

12 December 2020

Adolescent outcomes of childhood attention-deficit/hyperactivity disorder in a diverse community sample

1 reference

12 December 2020

Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children --- United States, 2003 and 2007.

1 reference

12 December 2020